Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Res. 2016 May 1;76(9):2778–2790. doi: 10.1158/0008-5472.CAN-16-0186

Figure 5. BRCA1 exon 11 mutations and patient survival.

Figure 5

(A) Kaplan-Meier estimates of cumulative survival according to BRCA1 mutation group of serous ovarian cancer patients (see Supplementary Tables S3 and S4).

(B) Primary breast and ovarian cancer patient tumors (unrelated to studies described in (A) were subject to qRT-PCR analysis for +11 and Δ11q expression. Values were normalized to a HKG control and expressed as a percentage of the values calculated for MDA-MB-231 cells. *P < 0.05.